Recent innovations have generated multiple approaches for eBV—“logic-based” and “artificial intelligence-based”—that create unique benefits and pose potential trade-offs. As a result, it’s critical for manufacturers to select the eBV approach that enables patients to initiate treatment, without compromising the quality, speed and confidence all stakeholders have come to expect from the benefit verification process.